TP53 and glioblastoma: TP53 is mutated or deleted in around 30% of glioblastomas [7]; for these patients, TP53 mutations may be used as a biomarker to stratify patients for dual mTORC1/2 inhibitor treatment, thus enhancing the effect of combination therapy employing AZD2014 or AZD8055 with temozolomide.